Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori Targeted nanoparticles for the treatment of H. pylori

Journal of Drug Targeting

Volumn 17, Issue 3, 2009, Pages 225-234

  Ramteke, Suman ^a   Ganesh, N ^b   Bhattacharya, S ^c   Jain, Narendra K ^d  

^a UNIVERSITY INSTITUTE OF TECHNOLOGY   (India)

^b Jawaharlal Nehru Cancer Hospital & Research Centre Bhopal   (India)

^c BIRLA INSTITUTE OF TECHNOLOGY   (India)

^d DR H S GOUR UNIVERSITY   (India)

Author keywords

Amoxicillin; Chitosan glutamate nanoparticles; Clarithromycin; H. pylori; Mucoadhesion; Omeprazole; Triple therapy

Indexed keywords

AMOXICILLIN; CHITOSAN; CLARITHROMYCIN; GLUTAMIC ACID; NANOPARTICLE; OMEPRAZOLE; DRUG CARRIER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; GELATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IN VIVO STUDY; ISOLATION PROCEDURE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; STOMACH JUICE; ANIMAL; CELL CULTURE; CHEMISTRY; DRUG COMBINATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; FEMALE; MALE; METHODOLOGY; RANDOMIZATION; SYNTHESIS;

AMOXICILLIN; ANIMALS; CELLS, CULTURED; CHITOSAN; CLARITHROMYCIN; DRUG CARRIERS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FEMALE; GLUTAMIC ACID; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MALE; MICE; NANOPARTICLES; OMEPRAZOLE; RANDOM ALLOCATION;

EID: 70149092333     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860902718649     Document Type: Article

References (34)

1. Allen A, Flemstrom G, Garner A, Kivilaa Kso E. (1993). Gastroduodenal mucosal protection. Physiol Rev, 73(4), 823-857.
2. Artursson P, Lindmark T, Davis SS, Illum L. (1994). Effect of chitosan on the permeability of monolayer of intestinal epithelial cells (Caco-2). Pharm Res, 11, 1358-1361.
3. Ascencio F, Guruge JL, Ljungh A, Megraud F, Wei S, Wadström T. (1990). Lectin typing of Helicobacter pylori. In: Malfertheiner P, Ditschuneit H. (Eds.), Helicobacter pylori, Gastritis and Peptic Ulcer (pp. 105-109). Berlin: Springer-Verlag.
4. Atherton JC, Cockayne A, Balsitis M, Kirk GE, Hawley CJ, Spiller RC. (1995). Detection of the intragastric sites at which Helicobacter pylori evades treatment with amoxicillin and cimetidine. Gut, 36, 670-674.
5. Bayerdorffer E, Lehn N, Harlz R, Manner CA, Oerkel M, Sauerbruth T, Stotte M. (1992). Difference in expression of Helicobacter pylori gastritis in antrum and body. Gastroenterology, 101, 1557-1582.
6. Bazzoli F, Pozzato P, Rokkas T. (2002). Helicobacter pylori: The challenge in therapy. Helicobacter, 7(1), 43-49.
7. Benaissa M, Babin P, Quellard N, Pezennec L, Cenatiempo A, Fauchere JL. (1996). Changes in Helicobacter pylori ultrastructure and antigens during conversion from the bacillary to the coccoid from. Infect Immun, 64, 2331-2335.
8. Blaser MJ. (1992). Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology, 102, 720-727.
9. Bode G, Malfertheiner P, Ditschuneit H. (1988). Pathogenic implications of ultrastructural findings in Campylobacter pylori related gastroduodenal disease. Scand J Gastroenterol, 23(142), 25-39.
10. Burton S, Washington N, Steele RJC, Masson R, Feely L. (1995). Intragastric distribution of ion-exchange resins: A drug delivery system for the topical treatment of the gastric mucosa. J Pharm Pharmacol, 47, 901-906.
11. Cooreman MP, Krausgrill P, Hengels KJ. (1993). Local gastric and serum amoxicillin concentrations after different oral application forms. Antimicrob Agents Chemother, 37, 1506-1509.
12. Dunn BE, Cohen H, Blaser MJ. (1997). Helicobacter pylori. Clin Microbiol Rev, 10, 720-741.
13. Dunn BE. (1993). Pathogenic mechanisms of Helicobacter pylori. Gastroenterol Clin N Am, 22, 43-57.
14. Goldstein IJ, Hughes RC, Monsingy M, Osawa T, Sharon N. (1980). What should be called a lectin. Nature, 285, 66.
15. Gustavson LE, Kaiser JF, Edmond AL, Locke CS, DeBartolo MI, Schneck DW. (1995). Effect of omeprazole on concentration of clarithromycin in plasma and gastric tissue at study state. Antimicrob Agents Chemother, 39(9), 2078-2083.
16. Hessey SJ, Spencer J, Wyatt JI, Sobala G, Rathbone BJ, Axon AT, Dixin MF. (1990). Bacterial adhesion and disease activity in Helicobacter-associated chronic gastritis. Gut, 31, 134-138.
17. Ishak RAH, Awad GAS, Mortada ND, Nour SAK. (2007). Preparation, in vitro and in vivo evaluation of stomach specific metronidazole loaded alginate beads as local antihelicobacter pylori therapy. J Control Release, 119, 207-214.
18. Kate V, Ananthakrishnan N. (2001). Treatment of Helicobacter pylori infection-a review. Ind J Pharmacol, 33, 410-416.
19. Kulkarni SK, Gupta M. (1999). Current concepts and drug therapy of Helicobacter pylori infection. Ind J Pharm Sci, 61(6), 323-334.
20. Liu Z, Lu W, Qian L, Zhang X, Zeng P, Pan J. (2005). In vitro and in vivo studies on mucoadhesive microspheres of amoxicillin. J Control Release, 102, 135-144. (Pubitemid 40093780)
21. Logan RP, Walker MM. (2001). ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of Helicobacter pylori infection. Br Med J, 323, 920-922.
22. Logan RPH, Gummett PA, Hegarty BT, Walker MM, Baron JH, Misiewicz. (1992). Clarithromycin and omeprazole for Helicobacter pylori. Lancet, 340, 239.
23. Pistole TG. (1981). Interaction of bacteria and fungi with lectins and lectin-like substances. Annu Rev Microbiol, 35, 85.
24. Ramteke S, Jain NK. (2008). Clarithromycin and omeprazole containing gliadin nanoparticles for the treatment of Helicobacter pylori. J Drug Targeting, 16(1), 65-72.
25. Ramteke S, Ganesh N, Bhattacharya S, Jain NK. (2008). Triple therapy based targeted nanoparticles for the treatment of H. pylori. J Drug Targeting, 16(9), 694-705.
26. Ramteke S, Umamaheshwari RB, Jain NK. (2006). Clarithromycin based oral sustained release nanoparticulate drug delivery system. Ind J Pharm Sci, 68(4), 479-484.
27. Sjostrom JE, Fryklund J, Kuhler T, Larsson H. (1996). In vitro antibacterial activity of omeprazole and its selectivity for Helicobacter spp. are dependent on incubation conditions. J Med Microbiol, 44I, 425-433.
28. Umamaheshwari RB, Jain NK. (2003). Receptor mediated targeting of lectin conjugated gliadin nanoparticles in the treatment of Helicobacter pylori. J Drug Targeting, 11(7), 415-424.
29. Umamaheshwari RB, Jain P, Jain NK. (2003a). Site-specific drug delivery of acetohydroxamic acid for the treatment of H. pylori. STP Pharma Sciences, 13(1), 41-48.
30. Umamaheshwari RB, Jain S, Bhadra D, Jain NK. (2003b). Floating microspheres bearing acetohydroxamic acid for the treatment of Helicobacter pylori. J Pharm Pharmacol, 55, 1607-1613.
31. Umamaheshwari RB, Jain S, Jain NK. (2003c). A new approach in gastroretentive drug delivery system using Cholestyramine. Drug Deliv, 10, 151-160.
32. Umamaheshwari RB, Ramteke S, Jain NK. (2004). Anti Helicobacter pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gabrils model. AAPS Pharma Sci Tech, 5(2), 1-9.
33. Unge P, Gad A, Gnarpe H, Olsson J. (1998). Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis-a pilot study. Scand J Gastroenterol, 24(167), 49-54.
34. Vaira D, Vakil N, Menegatti M. (2002). The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med, 136, 280-287.